Volz, A.K.; Dingemanse, J.; Haefeli, W.E.; Krause, A., Lehr, T (2017) A target-mediated drug disposition pharmacokinetic-pharmacodynamic model of bosentan and endothelin-1. Clinical Pharmacokinetics. online

Titze M, Schaaf O, Hofmann M, Sanderson M, Zahn S, Quant J, Lehr T (2017) An allometric pharmacokinetic/pharmacodynamics model for BI 893923, a novel IGF-1 receptor inhibitor. Cancer chemotherapy and pharmacology, online


Scherer, D.; Dings, C.; Böhm, M., Laufs, U. & Lehr, T. (2016) 'Alternative Treatment Regimens with the PCSK9 Inhibitors Alirocumab and Evolocumab: A Pharmacokinetic and Pharmacodynamic Modeling Approach', Journal of Clinical Pharmacology, online

Lott, D.; Dingemanse, J.; Krause, A. & Lehr, T. (2016) Modeling the effect of the selective S1P1 receptor modulator ponesimod on subsets of blood lymphocytes, Pharmaceutical Research, online

Titze, M. I.; Frank, J.; Ehrhardt, M.; Smola, S.; Graf, N. & Lehr, T. (2016), 'A generic viral dynamic model to systematically characterize the interaction between oncolytic virus kinetics and tumor growth', European Journal of Pharmaceutical Sciences 97, 38--46.

Titze, M. I.; Schaaf, O.; Hofmann, M. H.; Sanderson, M. P.; Zahn, S. K.; Quant, J. & Lehr, T. (2016), 'A comprehensive pharmacokinetic/pharmacodynamics analysis of the novel IGF1R/INSR inhibitor BI 893923 applying in vitro, in vivo and in silico modeling techniques', Cancer chemotherapy and pharmacology 77(6), 1303--1314.

Blank, A.; Markert, C.; Hohmann, N.; Carls, A.; Mikus, G.; Lehr, T.; Alexandrov, A.; Haag, M.; Schwab, M.; Urban, S. & others (2016), 'First-in-human application of the first-in-class hepatitis B and hepatitis D virus entry inhibitor myrcludex B', Journal of hepatology.

Bogomolov, P.; Alexandrov, A.; Voronkova, N.; Macievich, M.; Kokina, K.; Petrachenkova, M.; Lehr, T.; Lempp, F. A.; Wedemeyer, H.; Haag, M. & others (2016), 'Treatment of chronic hepatitis D with the entry inhibitor myrcludex B–first results of a Phase Ib/IIa study', Journal of hepatology.

Halton, J. L.; Lehr, T.; Cronin, L.; Lobmeyer, M. T.; Haertter, S.; Belletrutti, M.; Mitchell, L. G. & others (2016), 'Safety, tolerability and clinical pharmacology of dabigatran etexilate in adolescents', Thrombosis and Haemostasis 116(3), 461--471.

Lott, D.; Krause, A.; Dingemanse, J. & Lehr, T. (2016), 'Population pharmacokinetics of ponesimod and its primary metabolites in healthy and organ-impaired subjects', European Journal of Pharmaceutical Sciences 89, 83--93.

Lott, D.; Lehr, T.; Dingemanse, J. & Krause, A. (2016), 'Impact of Demographics, Organ Impairment, Disease, Formulation, and Food on the Pharmacokinetics of the Selective S1P1 Receptor Modulator Ponesimod Based on 13 Clinical Studies', Clinical Pharmacokinetics, 1--14.

Merk, H.; Zhang, S.; Lehr, T.; Müller, C.; Ulrich, M.; Bibb, J. A.; Adams, R. H.; Bracher, F.; Zahler, S.; Vollmar, A. M. & others (2016), 'Inhibition of endothelial Cdk5 reduces tumor growth by promoting non-productive angiogenesis', Oncotarget 7(5), 6088.

Moj, D.; Hanke, N.; Britz, H.; Frechen, S.; Kanacher, T.; Wendl, T.; Haefeli, W. E. & Lehr, T. (2016), 'Clarithromycin, Midazolam, and Digoxin: Application of PBPK Modeling to Gain New Insights into Drug–Drug Interactions and Co-medication Regimens', The AAPS Journal, 1--15.

Schaefer, N.; Wojtyniak, J.-G.; Kettner, M.; Schlote, J.; Laschke, M. W.; Ewald, A. H.; Lehr, T.; Menger, M. D.; Maurer, H. H. & Schmidt, P. H. (2016), 'Pharmacokinetics of (synthetic) cannabinoids in pigs and their relevance for clinical and forensic toxicology', Toxicology letters 253, 7--16.

Schneider, L. S.; Ulrich, M.; Lehr, T.; Menche, D.; Müller, R. & von Schwarzenberg, K. (2016), 'MDM2 antagonist nutlin-3a sensitizes tumors to V-ATPase inhibition', Molecular oncology.


L.S. Schneider, K. von Schwarzenberg, T. Lehr, M. Ulrich, R. Kubisch-Dohmen, J. Liebl, D. Trauner, D. Menche, A.M. Vollmar. Vacuolar-ATPase inhibition affects iron metabolism: a novel therapeutic option for breast cancer. Cancer Research 2015, in press, doi: 10.1158/0008-5472.CAN-14-2097

S.M. Ehrlich, J. Liebl, M.A. Ardelt, T. Lehr, E.N. De Toni, D. Mayr, L. Brandl, T. Kirchner, S. Zahler, A.L. Gerbes, A.M. Vollmar. Targeting cyclin dependent kinase 5 in hepatocellular carcinoma - a novel therapeutic approach. Journal of Hepatology 2015, in press, doi: 10.1016/j.jhep.2015.01.031.

L. Bortolussi, T. Krueger, T. Lehr, V. Wolf. Rule-Based Modelling and Simulation of Drug-Administration Policies. Conference Proceedings 2015 Spring Simulation Multi-Conference (SpringSim'15)


J.D. Gomez-Mantilla, U. Schaefer, V.G. Casabo, T. Lehr, C.M. Lehr. Statistical Comparison of Dissolution Profiles to Predict the Bioequivalence of Extended Release formulations. The AAPS Journal 2014; 16; 791 - 801

Reilly P*, Lehr T*, Haertter S, Connolly S, Yusuf S, Eikelboom J, Ezekowitz MD, Nehmitz G, Wang S, Wallentin L. The Effect of Dabigatran Plasma Concentrations and Patients Characteristics on the Frequency of Ischemic Stroke and Major Bleeding in Atrial Fibrillation Patients in the RE-LY Trial. J Am Coll Cardiol 2014; 63; 321 - 328; *co-first authors


 Haug KG, Staab A, Dansirikul C, Lehr T. A Semi-Physiological Model of Amyloid-β Biosynthesis and Clearance in Human Cerebrospinal Fluid: A Tool for Alzheimer's Disease Research and Drug Development. J Clin Pharmacol 2013; 53; 691 - 698. 

 Liesenfeld KH, Staab A, Härtter S, Formella S, Clemens A, Lehr T. Pharmacometric Characterization of Dabigatran Hemodialysis. Clin Pharmacokinet. 2013; 52: 453 - 462.

 Paré G, Eriksson N, Lehr T, Connolly S, Eikelboom J, Ezekowitz MD, Axelsson T, Haertter S, Oldgren J, Reilly P, Siegbahn A, Syvanen A-, Wadelius C, Wadelius M, Zimdahl-Gelling H, Yusuf S, Wallentin L. Genetic determinants of dabigatran plasma levels and their relation to bleeding. Circulation 2013;127(13):1404-12. Pubmed  

 Khadzhynov D, Wagner F, Formella S, Wiegert E, Moschetti V, Slowinski T, Neumayer H-, Liesenfeld KH, Lehr T, Härtter S, Friedman J, Peters H, Clemens A. Effective elimination of dabigatran by haemodialysis: A phase I single-centre study in patients with end-stage renal disease. Thromb Haemost 2013;109(4):596-605.  


Lehr T, Haertter S, Liesenfeld KH, Staab A, Clemens A, Reilly PA, Friedman J. Dabigatran etexilate in atrial fibrillation patients with severe renal impairment: Dose identification using pharmacokinetic modeling and simulation. J Clin Pharmacol 2012;52(9):1373-8.  

 Van De Werf F, Brueckmann M, Connolly SJ, Friedman J, Granger CB, Härtter S, Harper R, Kappetein AP, Lehr T, Mack MJ, Noack H, Eikelboom JW. A comparison of dabigatran etexilate with warfarin in patients with mechanical heart valves: The randomized, phase II study to evaluate the sAfety and pharmacokinetics of oraL dabIGatran etexilate in patients after heart valve replacemeNt (RE-ALIGN). Am Heart J 2012;163(6):931,937.  

 Dansirikul C, Lehr T, Liesenfeld KH, Haertter S, Staab A. A combined pharmacometric analysis of dabigatran etexilate in healthy volunteers and patients with atrial fibrillation or undergoing orthopaedic surgery. Thromb Haemost 2012;107(4):775-85.  

 Liesenfeld KH, Lehr T, Dansirikul C, Reilly PA, Connolly SJ, Ezekowitz MD, Yusuf S, Wallentin L, Haertter S, Staab A. Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non-valvular atrial fibrillation from the RE-LY trial: Reply to a rebuttal. Journal of Thrombosis and Haemostasis 2012;10(3):502-4.  

 Clemens A, Haertter S, Friedman J, Brueckmann M, Stangier J, Van Ryn J, Lehr T. Twice daily dosing of dabigatran for stroke prevention in atrial fibrillation: A pharmacokinetic justification. Curr Med Res Opin 2012;28(2):195-201.  


Lehr T, Yuan J, Hall D, Zimdahl-Gelling H, Schaefer HG, Staab A, MacGregor TR, Jayadev S. Integration of absorption, distribution, metabolism, and elimination genotyping data into a population pharmacokinetic analysis of nevirapine. Pharmacogenetics and Genomics 2011;21(11):721-30.  

 Liesenfeld KH, Lehr T, Dansirikul C, Reilly PA, Connolly SJ, Ezekowitz MD, Yusuf S, Wallentin L, Haertter S, Staab A. Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non-valvular atrial fibrillation from the RE-LY trial. Journal of Thrombosis and Haemostasis 2011;9(11):2168-75.  

 Lehr T, Yuan J, Zeumer D, Jayadev S, Ritchie MD. Rule based classifier for the analysis of gene-gene and gene-environment interactions in genetic association studies. BioData Mining 2011;4(1).  


Lehr T, Schaefer H-, Staab A. Integration of high-throughput genotyping data into pharmacometric analyses using nonlinear mixed effects modeling. Pharmacogenetics and Genomics 2010;20(7):442-50.  

 Lehr T, Narbe R, JÖns O, Kloft C, Staab A. Population pharmacokinetic modelling and simulation of single and multiple dose administration of meloxicam in cats. J Vet Pharmacol Ther 2010;33(3):277-86.  

 Lehr T, Staab A, Trommeshauser D, Schaefer HG, Kloft C. Quantitative pharmacology approach in alzheimer's disease: Efficacy modeling of early clinical data to predict clinical outcome of tesofensine. AAPS Journal 2010;12(2):117-29.  

 Lehr T, Staab A, Trommeshauser D, Schaefer HG, Kloft C. Semi-mechanistic population pharmacokinetic drug-drug interaction modelling of a long half-life substrate and itraconazole. Clin Pharmacokinet 2010;49(1):53-66.  

2007 bis 2009

Lehr T, Staab A, Tillmann C, Trommeshauser D, Schaefer H-, Kloft C. A quantitative enterohepatic circulation model: Development and evaluation with tesofensine and meloxicam. Clin Pharmacokinet 2009;48(8):529-42.  

 Lehr T, Staab A, Tillmann C, Nielsen EØ, Trommeshauser D, Schaefer HG, Kloft C. Contribution of the active metabolite M1 to the pharmacological activity of tesofensine in vivo: A pharmacokinetic-pharmacodynamic modelling approach. Br J Pharmacol 2008;153(1):164-74.  

 Lehr T, Staab A, Tillmann C, Trommeshauser D, Raschig A, Schaefer HG, Kloft C. Population pharmacokinetic modelling of NS2330 (tesofensine) and its major metabolite in patients with alzheimer's disease. Br J Clin Pharmacol 2007;64(1):36-48.